Functional Characterization of a Genetic Variant in the 5′ UTR of APC 1B Promoter in a Familial Adenomatous Polyposis Family
American Journal of Medical Genetics Part A · 2025
DOI: 10.1002/ajmg.a.63992 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Medical Genetics Part A, 2025. Verfasst von Brendon Young und 9 weiteren Autor:innen. Beteiligte Einrichtung: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Adenomatous Polyposis Coli, 5' Untranslated Regions, Promoter Regions, Genetic, Adenomatous Polyposis Coli Protein. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Pathogenic germline variants in the APC gene result in familial adenomatous polyposis (FAP) which can escalate into colon cancer. Standard clinical testing failed to identify pathogenic variants in a 4‐generation FAP family. We identified and assessed co‐segregation of a 5′ untranslated region (UTR) variant, NM_001127511.3 ( APC ) c.‐40G>A (GRCh37 chr5:112043375) that creates a potential out‐of‐frame AUG start codon. The segregation odds of pathogenicity for the APC c.‐40G>A variant are 159:1. Translation initiation confidence values for all possible AUGs in the 5′ UTR created by a single nucleotide substitution were calculated using PreTIS online tool. The ‐40G>A variant scored the highest possible confidence value. To test ‐40G>A as an initiating methionine, we created reporter constructs consisting of the entire 5′ UTR and first 81 bases of APC driving luciferase. When the ‐40G>A variant was present, luciferase activity was decreased to 14%–25% of the wild‐type construct. When the premature start codon created by the ‐40G>A variant was in‐frame with luciferase, we observed luciferase activity from this de novo false start site. Combined, our evidence supports classification of APC c.‐40G>A to likely pathogenic, presumably through squelching of the canonical AUG start codon. More importantly, it underlines the feasibility and importance of clinical laboratories to screen noncoding regions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
- Department of Internal Medicine, Division of Epidemiology, University of Utah, Salt Lake City, Utah, USA.
- Department of Oncological Sciences, University of Utah, Salt Lake City, Utah, USA.
- Department of Dermatology, University of Utah, Salt Lake City, Utah, USA.
- Legacy Cancer Institute, High Risk and Genetics Clinic, Legacy Health Systems, Portland, Oregon, USA.
- Department of Medicine and University of Vermont Cancer Center, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA.
ORCID-Profile: Deborah W Neklason
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Young, B., Neklason, D. W., Clark, K., Feng, B. J., Keener, M. B., Tuohy, T. M., Wood, A., McKinnon, W. C., Greenblatt, M. S., & Tavtigian, S. V. (2025). Functional Characterization of a Genetic Variant in the 5′ UTR of APC 1B Promoter in a Familial Adenomatous Polyposis Family. American Journal of Medical Genetics Part A. https://doi.org/10.1002/ajmg.a.63992
Vancouver
Young B, Neklason DW, Clark K, Feng BJ, Keener MB, Tuohy TM, et al. Functional Characterization of a Genetic Variant in the 5′ UTR of APC 1B Promoter in a Familial Adenomatous Polyposis Family. American Journal of Medical Genetics Part A. 2025. doi:10.1002/ajmg.a.63992
BibTeX
@article{Young2025,
author = {Young, Brendon and Neklason, Deborah W and Clark, Kathleen and Feng, Bing-Jian and Keener, Megan B and Tuohy, Thérèse M and Wood, Austin and McKinnon, Wendy C and Greenblatt, Marc S and Tavtigian, Sean V},
title = {Functional Characterization of a Genetic Variant in the 5′ UTR of APC 1B Promoter in a Familial Adenomatous Polyposis Family},
journal = {American Journal of Medical Genetics Part A},
year = {2025},
doi = {10.1002/ajmg.a.63992}
}
EUVIMED